These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34915973)

  • 1. Moral dilemma(s) in human papillomavirus vaccination - revisiting the role of the herd effect.
    Lehtinen M; Pimenoff VN
    Euro Surveill; 2021 Dec; 26(50):. PubMed ID: 34915973
    [No Abstract]   [Full Text] [Related]  

  • 2. Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma.
    Colzani E; Johansen K; Johnson H; Pastore Celentano L
    Euro Surveill; 2021 Dec; 26(50):. PubMed ID: 34915976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.
    Gray P; Kann H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel HM; Faust H; Dillner J; Lehtinen M
    PLoS Med; 2021 Jun; 18(6):e1003588. PubMed ID: 34097688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands.
    Simons JJM; Vida N; Westra TA; Postma MJ
    Vaccine; 2020 Jun; 38(30):4687-4694. PubMed ID: 32451211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review.
    Malagón T; Laurie C; Franco EL
    Expert Rev Vaccines; 2018 May; 17(5):395-409. PubMed ID: 29715059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
    Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
    Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Human Papillomavirus Vaccination, Rwanda and Bhutan.
    Baussano I; Sayinzoga F; Tshomo U; Tenet V; Vorsters A; Heideman DAM; Gheit T; Tommasino M; Umulisa MC; Franceschi S; Clifford GM
    Emerg Infect Dis; 2021 Jan; 27(1):1-9. PubMed ID: 33350922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic HPV vaccination for the prevention of cervical cancer.
    Hernandez BY
    Hawaii Med J; 2007 Jul; 66(7):190-1. PubMed ID: 17879858
    [No Abstract]   [Full Text] [Related]  

  • 9. [Human papillomavirus vaccination : pharmacovigilance data].
    Dib F; Launay O
    Rev Prat; 2020 Jan; 70(1):96-98. PubMed ID: 32877039
    [No Abstract]   [Full Text] [Related]  

  • 10. Human papillomavirus vaccination for adult women.
    Roteli-Martins CM; Magno V; Santos ALF; Teixeira JC; Nilma AN; Fialho SCAV
    Rev Bras Ginecol Obstet; 2022 Jun; 44(6):631-635. PubMed ID: 35820426
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaccinating against HPV: A Call to Action.
    Poh A
    Cancer Discov; 2016 Mar; 6(3):222-3. PubMed ID: 26842650
    [No Abstract]   [Full Text] [Related]  

  • 12. [Status of Human Papillomavirus Vaccination and Knowledge,Attitudes, and Influencing Factors towards Human Papillomavirus and Its Vaccines among University Students in Western China].
    Chen H; Zhou J; Huang Q; Si MY; Su XY; Li J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Aug; 43(4):545-550. PubMed ID: 34494524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness.
    Jit M; Prem K; Benard E; Brisson M
    Prev Med; 2021 Mar; 144():106354. PubMed ID: 33309871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computer-Animated Relational Agents in Human Papillomavirus Vaccination Education.
    Gogoi RP; Wallbillich JJ; Winer I; Morris R; Ritchie C; Larson S; Walker J; Bickmore T; Spencer E; Jang H; Kim S; Phalore J; Bui TC
    Obstet Gynecol; 2022 May; 139(5):913-915. PubMed ID: 35576351
    [No Abstract]   [Full Text] [Related]  

  • 15. Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination.
    Lehtinen M; Apter D
    Curr Opin Obstet Gynecol; 2015 Oct; 27(5):326-32. PubMed ID: 26308204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No Vacillation on HPV Vaccination.
    Sipp D; Frazer IH; Rasko JEJ
    Cell; 2018 Mar; 172(6):1163-1167. PubMed ID: 29522737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonavalent human papillomavirus vaccination as alternative treatment for genital warts.
    Bossart S; Gabutti MP; Seyed Jafari SM; Hunger RE
    Dermatol Ther; 2020 Jul; 33(4):e13771. PubMed ID: 32500585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the human papillomavirus (HPV) vaccine supply shortage on Tanzania's national HPV vaccine introduction.
    Li AJ; Kyesi F; Mwengee W; Mphuru A; Giattas MR; Shayo B; Nshunju R; Lyimo D; Loharikar A
    Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A26-A29. PubMed ID: 33509696
    [No Abstract]   [Full Text] [Related]  

  • 19. Lessons Learned From Human Papillomavirus Vaccination to Increase Uptake of Adolescent COVID-19 Vaccination.
    Ryan G; Askelson NM; Miotto MB; Goulding M; Rosal MC; Pbert L; Lemon SC
    J Adolesc Health; 2022 Mar; 70(3):359-360. PubMed ID: 35183319
    [No Abstract]   [Full Text] [Related]  

  • 20. Bowen disease of the nail apparatus with HPV16 positivity and resolution with human papillomavirus vaccination.
    Jeon YJ; Koo DW; Lee JS
    Br J Dermatol; 2020 Jul; 183(1):e1. PubMed ID: 32147811
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.